Genzyme has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, MA, allowing U.S. patients to return to full dosing in March. Also, new patients in the U.S. are eligible to begin Fabrazyme at full dosing levels. The FDA and the EMA approved the Framingham plant for the production of Fabrazyme in January 2012, and it is intended to alleviate shortages caused by the shutdown of Genzyme’s Allston, MA facility, which suffered from quality issues.   In Europ...